NeuroPace, Inc. (NPCE)
NasdaqGM · USD · Healthcare · Medical Devices
$12.99 (+0.62%) as of
Key statistics
- Market cap
- 445.87M
- Forward P/E
- -59.73
- EPS (TTM)
- -0.57
- Dividend yield
- 0.00%
- 52-week range
- 9.22 – 19.60
- Beta
- 1.87
- Revenue (TTM)
- 106.99M
- Profit margin
- -17.86%
- Analyst target
- $20.00
- Volume
- 67.31k
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Mountain View, CA, United States
- Employees
- 220
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.